9 Bond Court
Leeds LS1 2JZ
Full-time employees: 127
|Mr. Duncan Joseph Peyton||CEO & Exec. Director||102k||N/A||1970|
|Dr. Alexander James Stevenson||Chief Scientific Officer & Exec. Director||102k||N/A||1972|
|Mr. Stephen Dunbar||Fin. Director||N/A||N/A||N/A|
|Fay Weston||Head of Investor Relations||N/A||N/A||N/A|
|Mr. Laurence Dale||Gen. Counsel & Company Sec.||N/A||N/A||N/A|
|Dr. John D. Weinberg||Chief Medical Officer||N/A||N/A||1967|
4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company's development programs include Blautix for irritable bowel syndrome and Thetanix for paediatric crohn's disease. It also develops immuno-oncology products comprising MRx0518, MRx0573, and MRx1299 for solid tumors, and MRx0518 for pancreatic cancer; respiratory products, such as MRx-4DP0004 for asthma and COVID-19; central nervous system products, including MRx0005 and MRx0029 for neurodegeneration; and platform products comprising vaccines and autoimmune. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumours. The company was formerly known as Schosween 18 Limited. 4D pharma plc was founded in 2014 and is headquartered in Leeds, the United Kingdom.
4D pharma plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.